戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ral sinus anatomy in two patients with dural arteriovenous fistula.
2 zation and invasion of spleen parenchyma and arteriovenous fistula.
3 poptosis, and fibrosis in a porcine model of arteriovenous fistula.
4 er demonstrating right T7 to T8 spinal dural arteriovenous fistula.
5 n objective was the salvage of a functioning arteriovenous fistula.
6 nce angiography of his abdominal vessels and arteriovenous fistula.
7 lysis for the treatment of thrombosed native arteriovenous fistula.
8 edure for the treatment of thrombosed native arteriovenous fistula.
9  implemented an incentive if patients use an arteriovenous fistula.
10 as angiosarcomas might be correlated with an arteriovenous fistula.
11 nts, 20% of sarcomas arose at the site of an arteriovenous fistula.
12 prove patency rates following angioplasty of arteriovenous fistulas.
13 ure balloon angioplasty, in the treatment of arteriovenous fistulas.
14 iopathic intracranial hypertension and dural arteriovenous fistulas.
15 racranial haemorrhage in patients with dural arteriovenous fistulas.
16 xperience in endovascular treatment of dural arteriovenous fistulas.
17  32.7% of 74,194 patients transitioned to an arteriovenous fistula, 10.8% transitioned to an arteriov
18 nd initiating hemodialysis treatment with an arteriovenous fistula (2430 [15.8%] pre-COVID-19 vs 914
19 ge, cerebrovascular malformations, and dural arteriovenous fistula affecting the basal ganglia, their
20 ploring vein-to-artery anastomosis angles in arteriovenous fistulas, altering the graft-to-vein anast
21 approaches in mouse and human SMC, and human arteriovenous fistula and cardiac allograft vasculopathy
22 is upregulated in human intimal hyperplastic arteriovenous fistula and cardiac allograft vasculopathy
23                  Despite efforts to increase arteriovenous fistula and graft use, 80% of patients in
24 central venous catheter and transition to an arteriovenous fistula and graft, our observational cohor
25 ux hemodialysis may benefit patients with an arteriovenous fistula and patients with diabetes and tha
26 rebral haemorrhage due to intracranial dural arteriovenous fistula and presented our personal experie
27 cised if accessible, while hemorrhagic dural arteriovenous fistulas and distal/mycotic aneurysms are
28                                              Arteriovenous fistulas and pseudoaneurysms concerning in
29 mon conditions, such as venous malformation, arteriovenous fistula, and arteriovenous malformation) a
30        Findings included aneurysms, ectasia, arteriovenous fistulas, and anomalous origins.
31  rupture, arteriovenous malformations, dural arteriovenous fistulas, and cerebral cavernous malformat
32 ures observed in dysfunctional, hemodialysis arteriovenous fistulas, and that venous neointimal hyper
33                                     Although arteriovenous fistulas are considered superior to grafts
34                                              Arteriovenous fistulas are the ideal form of vascular ac
35 xistence of reasonable alternatives-that is, arteriovenous fistula, arteriovenous graft, and central
36 ssociations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central
37    Clinical practice guidelines recommend an arteriovenous fistula as the preferred vascular access f
38  1.2, mean hemoglobin > or = 11 g/dL, and an arteriovenous fistula as their vascular access.
39     In arteriovenous malformations and dural arteriovenous fistulas, ASL is very sensitive to detect
40 vascular lesions such as pseudoaneurysms and arteriovenous fistulas associated with the internal pude
41 of patients 3 months after implantation) for arteriovenous fistulas, averaged across all patient popu
42                                              Arteriovenous fistula (AVF) access improves survival in
43                  The persistence of a patent arteriovenous fistula (AVF) after transplantation may co
44 mes have been established with the use of an arteriovenous fistula (AVF) at first hemodialysis.
45 CorMatrix wrapped around the outflow vein of arteriovenous fistula (AVF) at the time of creation coul
46                   Creation of a hemodialysis arteriovenous fistula (AVF) causes aberrant vascular mec
47 ing minimal threshold diameters for surgical arteriovenous fistula (AVF) creation but fails to improv
48 nd dysfunction is a common observation after arteriovenous fistula (AVF) creation for hemodialysis ac
49 rmed routinely for vascular mapping prior to arteriovenous fistula (AVF) creation for hemodialysis bu
50 et al., published the first occurrence of an arteriovenous fistula (AVF) in a transplanted allograft
51  patients initiate hemodialysis (HD) with an arteriovenous fistula (AVF) in countries with universal
52                                              Arteriovenous fistula (AVF) is the preferred type of vas
53                                              Arteriovenous fistula (AVF) is the preferred type of vas
54                                              Arteriovenous fistula (AVF) is the preferred vascular ac
55                                              Arteriovenous fistula (AVF) maturation failure is the pr
56                          The pathogenesis of arteriovenous fistula (AVF) maturation failure is unclea
57 of the competing risk of death, high rate of arteriovenous fistula (AVF) maturation failure, and poor
58         The biological mechanisms underlying arteriovenous fistula (AVF) maturation in patients recei
59                                 Low rates of arteriovenous fistula (AVF) maturation prevent optimal f
60                          Stenosis within the arteriovenous fistula (AVF) of hemodialysis patients lea
61  access for patients undergoing hemodialysis-arteriovenous fistula (AVF) or arteriovenous graft (AVG)
62  and subsequently undergo placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG)
63 enefit when initiating hemodialysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG)
64 he optimal choice of initial vascular access-arteriovenous fistula (AVF) or graft (AVG)-remains contr
65 f upper extremity hemodialysis patients with arteriovenous fistula (AVF) stenoses.
66 is one of the most important determinants of arteriovenous fistula (AVF) success.
67 c variability in both incident and prevalent arteriovenous fistula (AVF) use among patients with ESRD
68                                              Arteriovenous fistula (AVF) was created in C57BL/J6 mice
69  percent were dialyzed through an autologous arteriovenous fistula (AVF), 49% through a prosthetic gr
70 senting at least one cerebral or spinal pial arteriovenous fistula (AVF), and to describe their clini
71 ue and the blood during surgical creation of arteriovenous fistula (AVF), we hypothesized that hypoxi
72 al hyperplasia (VNH)/venous stenosis (VS) in arteriovenous fistula (AVF).
73 dney disease require hemodialysis through an arteriovenous fistula (AVF).
74   Patients with end-stage renal failure need arteriovenous fistulas (AVF) to undergo dialysis.
75 ies on vascular access (VA) devices, such as arteriovenous fistulas (AVF), grafts (AVG), or catheters
76  (VNH) and venous stenosis (VS) formation in arteriovenous fistulas (AVF).
77 cident vascular access (ie, the composite of arteriovenous fistula [AVF] or arteriovenous graft [AVG]
78 g incident dialysis patients: (1) placing an arteriovenous fistula (AVF1st) as the initial access fol
79 primary patency rates at 1 year were 16% for arteriovenous fistulas (AVFs) and 23% for polytetrafluor
80 atives have emphasized the use of autogenous arteriovenous fistulas (AVFs) for hemodialysis, but thei
81                                        While arteriovenous fistulas (AVFs) have been the preferred di
82 estigated the hemodynamic characteristics of arteriovenous fistulas (AVFs) in murine models using mic
83 s transluminal angioplasty (PTA) of stenotic arteriovenous fistulas (AVFs) is performed to maintain o
84                                About half of arteriovenous fistulas (AVFs) require one or more interv
85 ntima formation causes the failure of 60% of arteriovenous fistulas (AVFs) within 2 years.
86 ptions for vascular access, including native arteriovenous fistulas (AVFs), arteriovenous grafts (AVG
87 ss the outcomes of angioplasty in autologous arteriovenous fistulas (AVFs).
88 hesia improves short-term blood flow through arteriovenous fistulas (AVFs).
89 le venous limb outward remodeling, preserved arteriovenous fistula blood flow, and prolonged primary
90 ces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proport
91 e prognosis when compared with those with an arteriovenous fistula, but the role of vascular access (
92 eding events requiring action, nerve injury, arteriovenous fistula, cardiac tamponade, arrhythmia, an
93                                           An arteriovenous fistula, created by artificially connectin
94 dministration (vs none) during radiocephalic arteriovenous fistula creation on early bleeding and thr
95 te a target trial of systemic heparin during arteriovenous fistula creation on short-term endpoints b
96 ing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1
97 rrhagic risk of intracranial low-grade dural arteriovenous fistulas (dAVFs), the benefits of routine
98 are causes of tinnitus include cranial dural arteriovenous fistulas (DAVFs), which are usually small
99 x (CVR) in patients with lateral sinus dural arteriovenous fistulas (DAVFs).
100 ion, both symptomatic and asymptomatic dural arteriovenous fistulas deserve clinical attention, struc
101 enotic lesions in dysfunctional hemodialysis arteriovenous fistulas during the 6 months after the pro
102 fe-sustaining hemodialysis, yet one-third of arteriovenous fistulas experience early failures.
103 fects suggests that these drugs might reduce arteriovenous fistula failure.
104    The relative rate of thrombosis of native arteriovenous fistulas for the highest quartile of intra
105 aparoscopic donor nephrectomy) and low-risk (arteriovenous fistula formation) operations.
106  error, interobserver variability, bleeding, arteriovenous fistula, graft loss, and even death.
107 left heart failure, high cardiac output from arteriovenous fistula, hypoxic lung diseases, and metabo
108 payment models linked with the prevalence of arteriovenous fistula in patients on hemodialysis.
109  of MCP-1 occurs in the venous segment of an arteriovenous fistula in rodents, and this vasculopathic
110 nalyzed the changes that evolve in a femoral arteriovenous fistula in the rat.
111 illin-resistant Staphylococcus aureus (MRSA) arteriovenous fistula infection and presented 5 weeks la
112                                        Dural arteriovenous fistula is a very rare cause of myelitis t
113                                       Native arteriovenous fistula is one of the important routes for
114                                          The arteriovenous fistula is the preferred type of vascular
115                  Pemafibrate also suppressed arteriovenous fistula lesion development.
116                        We conclude that this arteriovenous fistula model recapitulates the salient fe
117 n the venous segment of a murine model of an arteriovenous fistula, monocyte chemoattractant protein-
118 ovenous malformations (n = 3), and vertebral arteriovenous fistula (n = 1) underwent therapeutic embo
119 asation (n = 14), pseudoaneurysm (n= 2), and arteriovenous fistula (n = 1).
120 low was generated by construction of femoral arteriovenous fistulas on both sides.
121 at were positive for true or false aneurysm, arteriovenous fistula or malformation, or hemorrhage whe
122 iovenous access in the form of an autogenous arteriovenous fistula or nonautogenous arteriovenous gra
123 effect on mortality of programmed VA (PVA), (arteriovenous fistula or PTFE graft) and nonprogrammed V
124 nd angiography revealed a pseudoaneurysm and arteriovenous fistula originating from the right interna
125 pective analysis of the Consortium for Dural Arteriovenous Fistula Outcomes Research and the Internat
126 o evidence that statins improve experimental arteriovenous fistula patency and maturation, indicating
127                     The primary endpoint was arteriovenous fistula patency at 3 months.
128 us fistula blood flow, and prolonged primary arteriovenous fistula patency through day 42 (P<0.05 ver
129  with local anaesthesia improved medium-term arteriovenous fistula patency.
130 y to have nephrology care or have a graft or arteriovenous fistula placed before ESKD onset (nephrolo
131 isk [aRR], 0.47; 95% CI, 0.40-0.56; graft or arteriovenous fistula placed: aRR, 0.31; 95% CI, 0.17-0.
132                                              Arteriovenous fistulas placed surgically for dialysis va
133 n therapy in patients on dialysis undergoing arteriovenous fistula placement is warranted.
134 evelopment include carotid body ablation and arteriovenous fistula placement.
135 eudoaneurysms (PSA) and pseudoaneurysms with arteriovenous fistula (PSA + AVF), but its impact on ren
136 nts needing hemodialysis are advised to have arteriovenous fistulas rather than catheters because of
137 alendar year with elective open AAA repairs, arteriovenous fistula repairs, or carotid endarderectomy
138                                   Autogenous arteriovenous fistulas require 3 to 6 months to mature,
139 lar complications, including pseudoaneurysm, arteriovenous fistula, retroperitoneal hematoma, femoral
140 t pulsatile tinnitus caused by a small dural arteriovenous fistula revealed in computed tomography an
141 es after ligation injury and in failed human arteriovenous fistula samples after occlusion by dediffe
142  complete cure in most cases of spinal dural arteriovenous fistulas (SDAVF), there has been an increa
143 llow-up clinically and radiologically, dural arteriovenous fistulas should be kept in mind in the eti
144  predictive than duplex US of the outcome of arteriovenous fistula surgery.
145         Complications are less frequent with arteriovenous fistulas than with synthetic grafts.
146 tained vascular injuries (pseudoaneurysms or arteriovenous fistulas) that can be treated electively o
147 s thrombosis and dysfunction of hemodialysis arteriovenous fistulas, the latter caused, in part, by t
148 ed with patients undergoing dialysis with an arteriovenous fistula, those doing so via a catheter had
149        We concomitantly analyzed the in vivo arteriovenous fistula thrombogenic and inflammatory macr
150                   A serious adverse event of arteriovenous fistula thrombosis occurred in the patient
151 istered via central line, vascular shunt, or arteriovenous fistula to avoid thrombophlebitis.
152  the lower risk of mortality associated with arteriovenous fistula use in hemodialysis patients is du
153                                              Arteriovenous fistula use increased only minimally, from
154  30-day readmissions, hemodialysis adequacy, arteriovenous fistula use, and hemodialysis catheter use
155 , may contribute to the limited longevity of arteriovenous fistulas used for hemodialysis.
156                                              Arteriovenous fistula utilization at initial hemodialysi
157 ble housing included Hispanic ethnicity, non-arteriovenous fistula vascular access, lack of predialys
158                      In mice with a surgical arteriovenous fistula, volume overload and LV dilation w
159           Type of permanent vascular access (arteriovenous fistula vs synthetic graft), analyzed usin
160  model, venous neointimal hyperplasia in the arteriovenous fistula was also exacerbated.
161                Finally, in a rat model of an arteriovenous fistula, we localized expression of MCP-1
162 val time of target lesion primary patency in arteriovenous fistulas, we designed an investigator-led
163 jacent to vessels, and PSAs with concomitant arteriovenous fistula were referred to MC (n=145, 34%).
164 restenotic lesions in native upper-extremity arteriovenous fistulas were eligible for participation.
165  was reviewed, and 25 patients with 28 dural arteriovenous fistulas were identified.
166 -dependent when waitlisted, individuals with arteriovenous fistulas were significantly less likely th
167 ith the low-flux group for the subgroup with arteriovenous fistulas, which constituted 82% of the stu
168                             Patients with an arteriovenous fistula who were undergoing an angioplasty
169 d by a kink, complete venous thrombosis, and arteriovenous fistula with pseudoaneurysm formation.

 
Page Top